Conclusion: In conclusion, SUT might preserve membrane viability even at lower dosages. Although this is an experimental study, we believe that SUT after controlled trials may be a therapeutic agent for long-term peritoneal dialysis patients.
PMID: 21240876 [PubMed - as supplied by publisher] (Source: Journal of Nephrology)